Reckitt Benckiser reported stronger-than-expected third-quarter net revenues of £3.6 billion, marking a 7.0% like-for-like increase that surpassed analyst expectations, driven by robust growth in core products like Durex and Dettol and strong performance in emerging markets. The company maintained its full-year 2025 guidance for revenue growth, anticipating adjusted operating profit and EPS to increase, while also completing the first £250 million tranche of its £1 billion share buyback program and progressing with the divestment of its Essential Home brands.
Reckitt Benckiser reported a stronger-than-expected third-quarter performance, with net revenues reaching £3.6 billion, marking a 7.0% like-for-like (LFL) increase that surpassed analyst expectations of "just over 6%". Core Reckitt products drove this outperformance with 6.7% LFL growth against a 5.4% consensus, notably supported by an improvement in volumes to 3.4% from 1.2% in the first half. Growth was significantly propelled by a 15.5% LFL increase in emerging markets and a return to growth in developed markets, with intimate wellness (Durex) and germ protection (Dettol) categories outperforming due to innovation. While Mead Johnson infant nutrition posted 22.0% LFL growth against a weak prior-year comparator, the Essential Home brands declined 4.9%, with a mid-single-digit decline now expected for 2025. The company maintained its full-year 2025 guidance for group LFL net revenue growth between 3% and 4%, and Core Reckitt exceeding 4%, anticipating increases in adjusted operating profit and diluted earnings per share. Furthermore, Reckitt completed the first £250 million tranche of its £1 billion share buyback program and confirmed the planned divestment of Essential Home remains on track for year-end completion.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment